BillionToOne, Inc. (BLLN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BillionToOne, Inc. (BLLN) Healthcare & Pipeline Overview

BillionToOne, Inc. is a precision diagnostics firm leveraging a proprietary molecular counting platform to enhance disease detection. Specializing in non-invasive prenatal screening (UNITY Complete) and liquid biopsy for cancer (Northstar Select, Northstar Response), the company quantifies DNA molecules at single-count levels, positioning itself in the evolving medical diagnostics and research sector.

What Is the Investment Thesis for BLLN?

BillionToOne, Inc. presents an investment thesis centered on its proprietary molecular counting platform, which offers superior precision in detecting DNA molecules at the single-count level. This technological edge underpins its suite of diagnostic products, UNITY Complete for non-invasive prenatal screening and Northstar Select/Response for liquid biopsy in oncology, addressing high-growth markets. The company's robust gross margin of 70.4% indicates strong operational efficiency and pricing power for its specialized tests. While the P/E ratio of 180.87 suggests a growth-oriented valuation, it reflects investor confidence in the future earnings potential driven by market expansion and new product development. Key growth catalysts include increasing adoption of non-invasive diagnostic methods, the expanding utility of liquid biopsies in cancer management, and potential for broader clinical applications of its platform. The company's focus on enhancing disease detection through quantitative biology positions it to capture significant market share in the evolving medical diagnostics and research industry.

Based on FMP financials and quantitative analysis

BLLN Key Highlights

Market capitalization stands at $4.53B, reflecting its valuation in the precision diagnostics sector.

• A P/E ratio of 180.87 indicates significant investor expectations for future earnings growth, typical for high-growth biotech firms.
• The company maintains a strong gross margin of 70.4%, demonstrating efficient cost management relative to revenue from its diagnostic tests.
• A profit margin of 7.1% highlights the company's ability to convert revenue into net income, even while investing in R&D and market expansion.
• BillionToOne, Inc. was incorporated in 2016 and has grown to 620 employees, showcasing rapid expansion and operational scaling since its founding.

Who Are BLLN's Competitors?

BLLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BLLN's Key Strengths?

Proprietary molecular counting platform offers high precision in DNA molecule detection.

• Diverse product portfolio addressing both prenatal screening and oncology liquid biopsy markets.
• Strong gross margin of 70.4% indicates efficient operations and value proposition.
• Focus on non-invasive diagnostic solutions aligns with current healthcare trends.
• Experienced leadership team guiding strategic development and commercialization.

What Are BLLN's Weaknesses?

High P/E ratio (180.87) suggests high market expectations, potentially leading to volatility.

• Relatively young company (incorporated 2016) with a shorter track record compared to established players.
• Dependence on regulatory approvals and reimbursement policies for market access and growth.
• Beta of -0.05 indicates low correlation with market, but also potential for idiosyncratic risks.
• Limited geographic reach currently, primarily headquartered in the U.S.

What Could Drive BLLN Stock Higher?

BLLN catalyst: Positive clinical trial results for new indications or expanded panels for UNITY Complete or Northstar tests, potentially broadening market access.

• Securing key regulatory approvals (e.g., FDA clearance or CE Mark) for new diagnostic products or expanded claims for existing ones, opening new markets.
• Increased adoption rates and market penetration of UNITY Complete in non-invasive prenatal screening, driving revenue growth.
• Expansion of reimbursement coverage for Northstar Select and Northstar Response by major insurance providers, enhancing accessibility for patients.
• Formation of strategic partnerships with pharmaceutical companies for companion diagnostics development, leveraging the molecular counting platform.

What Are the Key Risks for BLLN?

Rich valuation — a P/E of 180.87 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Intense competition in the molecular diagnostics market could lead to pricing pressures or slower market share gains.
• Regulatory hurdles and delays in obtaining necessary approvals for new tests or expanded claims could impede product commercialization.
• Challenges in securing broad and favorable reimbursement policies for its diagnostic tests, impacting market adoption and profitability.
• Rapid technological advancements by competitors could render existing platforms or tests less competitive or obsolete.
• Dependence on a limited number of key products for revenue generation, making the company vulnerable to product-specific market shifts or failures.

What Are the Growth Opportunities for BLLN?

• Expansion of UNITY Complete's market reach: The non-invasive prenatal screening market is projected to grow significantly, driven by increasing demand for early and accurate fetal health assessments. BillionToOne can capitalize on this by expanding UNITY Complete's availability into new geographic regions, including international markets, and potentially broadening its panel to include additional genetic conditions. This expansion would leverage the platform's precision to capture a larger share of a market valued in the billions, enhancing revenue streams over the next 3-5 years.
• Increased adoption of Northstar Select for liquid biopsy: The liquid biopsy market for cancer diagnostics is experiencing rapid growth, fueled by its non-invasive nature and ability to provide real-time insights into tumor genetics. BillionToOne can drive growth by increasing clinical adoption of Northstar Select among oncologists and healthcare providers, demonstrating its utility in treatment selection and recurrence monitoring. Educational initiatives and partnerships with cancer centers could accelerate its penetration into this multi-billion-dollar market over the next 2-4 years.
• Broader utilization of Northstar Response for cancer monitoring: Northstar Response offers a unique approach to longitudinal cancer burden determination through methylation assessment. As cancer care shifts towards more personalized and continuous monitoring, the demand for such tests will rise. BillionToOne can expand its market by securing broader reimbursement coverage and integrating Northstar Response into standard clinical guidelines for various cancer types, establishing it as a go-to solution for tracking treatment efficacy and disease progression over the next 3-5 years.
• Development of new molecular diagnostic tests: Leveraging its versatile molecular counting platform, BillionToOne has the opportunity to develop and launch new diagnostic tests beyond its current prenatal and oncology offerings. This could include tests for early detection of other diseases, infectious diseases, or pharmacogenomics. By expanding its product pipeline, the company can tap into new market segments and diversify its revenue streams, capitalizing on the platform's inherent precision and scalability over a 5-year horizon.
• Strategic partnerships and collaborations: Forming strategic alliances with pharmaceutical companies, research institutions, or other diagnostic providers can significantly accelerate BillionToOne's market penetration and product development. Such partnerships could facilitate co-development of companion diagnostics, expand research capabilities, or provide access to broader distribution channels. These collaborations could unlock new market opportunities and enhance the company's competitive standing within the precision diagnostics landscape, with potential impacts unfolding over the next 1-3 years.

What Threats Does BLLN Face?

• Intense competition from established diagnostic companies and other biotech innovators.
• Rapid technological obsolescence in the fast-paced molecular diagnostics field.
• Stringent and evolving regulatory landscape for diagnostic tests.
• Challenges in securing broad reimbursement coverage from payers.
• Potential for intellectual property disputes or new entrants with disruptive technologies.

What Are BLLN's Competitive Advantages?

• Proprietary molecular counting platform designed for single-count DNA molecule detection, offering superior sensitivity and accuracy.
• Unique suite of specialized diagnostic tests (UNITY Complete, Northstar Select, Northstar Response) addressing critical clinical needs.
• Strong intellectual property protection around its core technology and diagnostic assays.
• Expertise in translating complex molecular biology into clinically actionable diagnostic solutions.
• Early mover advantage in specific applications of its precision diagnostics platform.

What Does BLLN Do?

BillionToOne, Inc., incorporated in 2016 and headquartered in Menlo Park, California, operates as a precision diagnostics company dedicated to quantifying biology to create advanced molecular diagnostics. The company's foundational technology is a proprietary molecular counting platform, meticulously engineered to detect and measure DNA molecules at the single-count level. This innovative capability is crucial for significantly enhancing the accuracy and sensitivity of disease detection across various medical fields. BillionToOne has strategically developed a suite of products addressing critical diagnostic needs. Among its flagship offerings is UNITY Complete, a comprehensive non-invasive prenatal screen. This test allows for the assessment of fetal risk for aneuploidies, recessive conditions, and fetal antigens, all from a maternal blood draw, providing crucial information without invasive procedures. In the oncology space, the company offers Northstar Select, a sophisticated liquid biopsy test designed to identify a detailed list of mutations present in a tumor. This includes various mutation types such as deletions, insertions, and point mutations, offering valuable insights for personalized cancer treatment. Complementing this, Northstar Response provides longitudinal determination of cancer burden through methylation assessment, enabling ongoing monitoring of disease progression and treatment efficacy. BillionToOne's commitment to precision and innovation positions it as a key player in the rapidly evolving landscape of molecular diagnostics, aiming to deliver more accurate and earlier disease detection solutions to the healthcare market.

What Products and Services Does BLLN Offer?

• Develops and commercializes precision molecular diagnostics.
• Utilizes a proprietary molecular counting platform for highly sensitive DNA molecule detection.
• Offers UNITY Complete, a non-invasive prenatal screen for fetal aneuploidies, recessive conditions, and antigens.
• Provides Northstar Select, a liquid biopsy test identifying tumor mutations (deletions, insertions, point mutations).
• Markets Northstar Response, a test for longitudinal cancer burden determination via methylation assessment.
• Focuses on quantifying biology to enhance the accuracy and sensitivity of disease detection.
• Aims to improve patient outcomes through early and precise diagnostic insights.
• Operates within the Medical - Diagnostics & Research industry.

How Does BLLN Make Money?

• Generates revenue through the sale of its proprietary diagnostic tests, such as UNITY Complete, Northstar Select, and Northstar Response.
• Relies on clinical adoption and reimbursement for its non-invasive prenatal screening and liquid biopsy products.
• Monetizes its molecular counting platform by applying it to various diagnostic applications.
• Focuses on high-value diagnostic services that offer superior precision and clinical utility.
• Potentially earns revenue from licensing its platform technology or through research collaborations.

What Industry Does BLLN Operate In?

BillionToOne, Inc. operates within the dynamic and rapidly expanding Medical - Diagnostics & Research industry, a critical segment of the broader Healthcare sector. This industry is characterized by continuous innovation, particularly in molecular diagnostics, where advancements in genetic sequencing and biomarker detection are transforming patient care. BillionToOne's focus on a molecular counting platform positions it at the forefront of precision medicine, an area experiencing substantial growth due to increasing demand for early disease detection, personalized treatment, and non-invasive testing methods. The market for non-invasive prenatal testing (NIPT) and liquid biopsies for oncology is projected to grow significantly, driven by technological improvements and broader clinical adoption. The competitive landscape includes established diagnostic giants and emerging biotech firms, all vying for market share through innovation, regulatory approvals, and strategic partnerships. BillionToOne differentiates itself through its unique single-count DNA molecule detection capability, aiming to offer superior accuracy and sensitivity in its diagnostic offerings.

Who Are BLLN's Key Customers?

• Pregnant individuals and their healthcare providers seeking non-invasive prenatal screening.
• Oncologists and cancer patients requiring liquid biopsy for mutation detection and treatment guidance.
• Healthcare systems and hospitals integrating advanced molecular diagnostics into their services.
• Research institutions and pharmaceutical companies interested in precision diagnostic capabilities.
• Individuals undergoing cancer treatment who require longitudinal monitoring of disease burden.

Company Profile

BillionToOne, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Oguzhan Atay. BLLN has traded publicly since 2025.

Return on equity for BillionToOne, Inc. stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. BLLN trades at a trailing price-to-earnings ratio of 180.87, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.6%, the inverse of the P/E and a quick read on earnings relative to price.

BLLN Valuation & Market Position

With a $4.53B market cap, BillionToOne, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $120.00 to $130.00, with a consensus of $125.00. At the current price of $98.51, that implies approximately 27% upside potential. Relative to its peer group, BLLN's quantitative score of 96/100 is above the peer average of 54/100.

Quarterly Financial Performance: BillionToOne, Inc.

Revenue for BillionToOne, Inc. came in at $109.4M during Jun 2026. The company recorded net income of $8.1M, with diluted EPS of $0.15. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, BLLN averaged $0.16 in diluted EPS.

BillionToOne, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 15.51 places it in the safe zone, indicating low near-term bankruptcy risk.

BillionToOne, Inc. has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 639.3% above estimates on average.

Wall Street analysts project BillionToOne, Inc. revenue of about $455.7M for fiscal 2026, with EPS near $0.79. The estimate reflects 7 contributing analysts.

BLLN Financials

BLLN Latest News

BLLN Analyst Consensus

BLLN MoonshotScore

Common Questions About BLLN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources